新闻

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Financial Times

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论,并结合市场和 OSINT 背景分析。